A fundamental analysis of Sequent Scientific (SEQUENT) covering revenue trends, profitability, valuation, and shareholding patterns.
Sequent Scientific Revenue Trend
In FY2025, Sequent Scientific posted revenue of ₹1,551 Cr, up 12.4% from ₹1,381 Cr a year earlier.
The 10-year revenue CAGR of 13.3% is a good number — Sequent Scientific's top line has expanded meaningfully from ₹443 Cr to ₹1,551 Cr.
Sequent Scientific is a mid-sized pharmaceuticals company by revenue, with a top line of ₹1,551 Cr.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,551 Cr | +12.4% |
| FY2024 | ₹1,381 Cr | -3.3% |
| FY2023 | ₹1,427 Cr | +0.3% |
| FY2022 | ₹1,424 Cr | +4.6% |
| FY2021 | ₹1,362 Cr | — |
View Sequent Scientific's full 10-year revenue trend with CAGR analysis →
Sequent Scientific Profitability
Earnings per share (diluted) were ₹0.85 in FY2025, up from ₹-1.44.
Is Sequent Scientific Undervalued
Per the P/E Ratio model, Sequent Scientific has an estimated intrinsic value of ₹57 (71.6% downside).
Sequent Scientific shares are currently trading at ₹201.17.
Craytheon also calculates intrinsic value using the EPS Growth model. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹57 | 71.6% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
See all valuation models for Sequent Scientific with detailed assumptions →
Sequent Scientific Balance Sheet
Proportional view as of 22 Jan 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹16.02B (up 4.0% YoY from ₹15.40B).
Top categories: Inventories (24.1%), Receivables (22.7%), Intangibles & Goodwill (18.8%).
Of the ₹16.02B in liabilities and equity, 48.1% is shareholder equity, 30.0% is interest-bearing debt, and 21.9% is operating liabilities. Over the year, debt is down 1.3% and equity is up 8.1%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 627.28M |
| Receivables | 3.63B |
| Inventories | 3.85B |
| Property, Plant & Equipment | 2.47B |
| Investments | 50,000 |
| Intangibles & Goodwill | 3.02B |
| Other Assets | 2.42B |
| Category | Value |
|---|---|
| Equity | 7.70B |
| Short-term Debt | 1.81B |
| Long-term Debt | 3.00B |
| Trade Payables | 2.57B |
| Other Liabilities | 936.26M |
Sequent Scientific — The Bottom Line
What should investors take away from Sequent Scientific's (SEQUENT) latest numbers? Here's the summary.
Revenue of ₹1,551 Cr in FY2025, up 12.4% year-over-year.
Long-term revenue has been compounding at 13.3% annually over 10 years.
The company is profitable, with a net margin of 2.1% and net income of ₹32.3 Cr.
The P/E Ratio model implies 71.6% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Sequent Scientific's detailed profile on Craytheon.